Rangwala to be CMO at Karyopharm
Plus Jones becomes CFO at Sense, and updates from Enzo, Dice and more
Reshma Rangwala will be CMO at Karyopharm Therapeutics Inc. (NASDAQ:KPTI) starting in mid-April. Rangwala, a former Merck & Co. Inc. (NYSE:MRK) distinguished scientist, joins Karyopharm from Aravive Inc. (NASDAQ:ARAV) where she was CMO, and succeeds Jatin Shah, whose resignation was announced last month. The company also announced that co-founders Sharon Shacham and Michael Kauffman were stepping down as CSO and senior clinical advisor, respectively. Kauffman is also resigning his membership of the board, although Shacham will continue to serve on the company’s scientific advisory board. Karyopharm’s shares fell 25% four weeks ago after FDA said that the company would need to conduct another study of XPO1 inhibitor Xpovio selinexor to treat endometrial cancer to support an NDA seeking its approval in that indication.
Diagnostics company Enzo Biochem Inc. (NYSE:ENZ) named Chief Commercial Officer Kara Cannon as COO and expanded the role of CFO David Bench to include that of SVP, treasurer, and corporate secretary. The company, which hired Hamid Erfanian as CEO last October, also said it was hiring for the positions of vice president of commercialization, director of regulatory affairs, director of research & development, and general counsel...